Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Plataforma de miocitos cardíacos humanos para descubrimiento de medicamentos y evaluación de la toxicidad

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOSG20160929003
Publicado:
11/01/2017
Caducidad:
11/01/2018
Resumen:
Un grupo de instituciones de salud pública de Singapur ha desarrollado una tecnología para el suministro rentable de miocitos cardíacos humanos con una plataforma de detección rápida destinada a la evaluación de la seguridad de medicamentos y al descubrimiento de fármacos en la industria biofarmacéutica. La plataforma evita problemas de evaluación inadecuada de la toxicidad de medicamentos en la práctica actual de la industria y dificultades en el descubrimiento de medicamentos. Se buscan pymes, multinacionales, universidades o centros de I+D con el fin de establecer acuerdos de licencia, joint venture o investigación.

Details

Tittle:
Human cardiac myocyte platform for drug discovery and drug toxicity
Summary:
A Singapore group of public healthcare institutions has developed a technology which enables cost-effective supply of human cardiac myocytes with rapid screening platform for drug safety evaluation and targeted drug discovery for the biopharmaceutical industry. The group is seeking commercialization partnerships with SMEs of any sizes, MNEs, universities or R-Y-D institutions with interests to explore a license, joint venture or research cooperation agreement.
Description:
Off-target effects of drugs on cardiac myocytes pose adverse side effects that could seriously jeopardize patient safety. No targeted preventive platform is presently available due to the lack of human cardiac myocytes for pre-emptive screening against potential toxicities of drugs.

This technology provides straightforward access to human cardiac myocytes and easy platform for drug testing and screening of pharmaceutical agents. This circumvents problems of aberrant and inaccurate evaluation of drug toxicity in current industry practice and bottleneck in drug discovery. Human cardiac myocytes produced have been independently tested to show verifiable characteristics of cardiac biology and drug response performance synonymous to human heart in multiple laboratories.

The technology consists of processes to produce readily available human cardiac myocytes and easy testing platform for drug toxicity and drug discovery for clinically prescribed drugs or experimental pharmaceuticals. Our human cardiac myocytes respond to all four classes of anti-arrhythmics and provide readouts conforming to plasma therapeutic range of the tested drugs.

This proposed technology provides a rapid inroad into drug toxicity testing and drug discovery space by leveraging on cost-effective human cardiac myocyte production technology supported by US FDA compliant (HESI CiPA initiatives*) bench-top evaluation platform.

The Singapore healthcare group is seeking to partner:

- R-Y-D institutions and universities interested in further develop this technology via research cooperation agreement

- SMEs and MNEs interested in license agreement (the partner will incorporate the technology into their products) or joint venture agreement (possible legal entity set up with equity stakes from both parties to develop new products for both the EU and Asia markets)

The complete chain of drug testing and screening platform is made available to partners who prefer a turnkey solution in drug safety and evaluation.

*Legend:
CiPA - Comprehensive in Vitro Proarrhythmia Assay
HESI - Health and Environmental Sciences Institute
Advantages and Innovations:
Cost-effective supply of high quality human cardiac myocytes is made readily available for regulatory authorities, biopharmaceutical industry and drug safety organizations for testing and screening for drug safety and drug discovery.

The complete chain of drug testing and screening platform is made available to partners who prefer turnkey solution in drug safety and evaluation.

The technology offers human cardiac myocytes for drug toxicity and safety screening that complements the HESI/FDA CiPA initiatives of using human heart cells for drug safety evaluation in a cost-effective way that is supported by a compliant result readouts platform. In order to benefit from the potential of human cardiac myocytes for molecular, structural and functional research, a highly efficient, cost effective and clinically compliant method, which is easily reproducible, is desirable.
Stage of Development:
Prototype available for demonstration
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
Patent filed in EP, US and Singapore

Partner sought

Type and Role of Partner Sought:
The type and role of the partner would be to either:

- commercialize the technology via licensing to introduce new products to the market (SMEs and MNEs) or
- to further develop this technology via research cooperation agreement (R-Y-D institutions and universities) or
- establish a joint-venture to meet the demand-driven needs of the addressable market (SMEs and MNEs).

Specific area of activities of the partner includes, but not limited to:
- Biotechnology,
- Pharmaceutical industry
- Diagnostics
- Medical devices

Client

Type and Size of Client:
R&D Institution
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English

Keywords

Technology Keywords:
06002002 Biología celular y molecular
06001012 Investigaciones médicas
06001 Medicina, salud humana
06001015 Productos farmacéuticos / medicamentos